2800 Plymouth Road
NCRC, Building 26
48 articles with Lycera
Lycera Announces Presentations at the 2018 ESMO Congress for LYC-55716, a First-in-class RORgamma Agonist Candidate
Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, today announced that two abstracts highlighting data from ongoing clinical studies of the company's novel immuno-oncology therapeutic candidate, LYC-55716,
Lycera to Present on First-in-class RORgamma Agonist Candidate LYC-55716 at the 2018 ASCO Annual Meeting
Lycera Corp. announced presentations of the company's novel immuno-oncology therapeutic candidate, LYC-55716, to take place during the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, today announced the publication of new preclinical research findings describing the potential utility of the Company's most advanced cancer immunotherapy platform, selective RORgamma agonists, in adoptive cell therapy applications.
Now in its fourth day, the American Association of Cancer Research (AACR) Annual Meeting 2018 held in Chicago, has had plenty of news, much of it preclinical or early-clinical data.
Lycera Presents Clinical Safety and Dose Selection Results for First-in-class RORgamma Agonist Candidate LYC-55716 at the 2018 AACR Annual Meeting
Clinical benefit observed in multiple patients treated with single agent RORgamma Agonist
Lycera Announces Initiation of Phase Ib Study of Novel Immuno-Oncology Candidate LYC-55716 in Combination with Pembrolizumab
Lycera's Phase 1b study is expected to enroll a total of approximately 18 patients with metastatic NSCLC.
Lycera Presents Tumor Selection Rationale for Phase IIa Study at SITC's 2017 Annual Meeting for RORgamma Agonist, LYC-55716
Lycera has selected multiple tumor types, including non-small-cell lung cancer, squamous cell head and neck cancer, ovarian cancer, urothelial cancer, renal cell cancer, and esophageal / gastric cancer for inclusion in the Phase IIa portion of the ARGON study.
Lycera Announces Advancement of Novel Immuno-Oncology Candidate LYC-55716 RORgamma Agonist into Phase IIa
Lycera today announced the initiation of the Phase 2a portion of the company's Phase 1/2a ARGON study of its novel immuno-oncology therapeutic candidate, LYC-55716 is a first-in-class oral, selective retinoic acid-related orphan receptor-gamma (RORgamma) agonist, designed to reprogram the immune system in patients with advanced, relapsed or refractory solid tumors.
Lycera Presents Encouraging Safety Results From Phase I ARGON Study Of LYC-55716 At The European Society For Medical Oncology (ESMO) Congress
Lycera Announces Initiation Of Phase 1/2a Study ARGON Of Immuno-Oncology Candidate LYC-55716 In Patients With Advanced Solid Tumors
Lycera Announces Initiation Of Phase 2 UPRISE Clinical Trial Of LYC-30937-EC For Patients With Moderate Psoriasis
Lycera Announces Publication Of Immuno-Oncology Research, Demonstrating Differentiated Mechanism Of RORgamma Agonists
Lycera Announces Initiation Of Phase 2 Clinical Trial Of LYC-30937-EC In Patients With Ulcerative Colitis
Lycera Congratulates Dr. Peter L. Toogood For His Receipt Of The 2016 Heroes Of Chemistry Award From The American Chemical Society
Lycera Announces Presentations Of Positive Preclinical Results For Lead Candidate LYC-30937 And For Selective Rho Kinase Inhibitor Program At The 11th Congress Of The European Crohn's And Colitis Organization (ECCO)
Lycera Announces Celgene Has Exercised Its Option To License Portfolio Of Ex Vivo RORgamma Agonist Compounds Under Global Strategic Collaboration
Lycera Announces Progress In Immuno-Oncology Program To Be Presented At Society For Immunotherapy Of Cancer (SITC) 2015 Annual Meeting